---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-26-000019"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:53:27.175975+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone

## Summary
- Borrowed $400M initial term loan to repay existing credit agreement from January 2023.
- Additional $300M delayed draw facility for acquisitions available through August 2027.
- Uncommitted incremental capacity up to $500M; loans priced at SOFR + 5.00%.
- Credit agreement matures April 2031; secured by substantially all assets.
- Must maintain minimum $50M qualified cash tested quarterly.

## SEC filing metadata
- accession: 0002019410-26-000019
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-26-000019
- JSON: https://secwatch.observer/filing/0002019410-26-000019.json
- Plain text: https://secwatch.observer/filing/0002019410-26-000019.txt

## Source-grounded claims
- claim_id: 3f4acc9b8602a48859e8ac04773926e22112e7e7
  claim: Caris Life Sciences, Inc. incurred credit facility of $400,000,000 initial term loan, up to $300,000,000 delayed draw facility, and up to $500,000,000 uncommitted incremental with Blue Owl Capital and Blackstone at Term SOFR Rate or Base Rate plus 5.00% or 4.00%, respectively maturing Initial Term Facility matures in April 2031; Delayed Draw Facility available through August 2027.
  evidence_excerpt: On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou
  evidence_url: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm
- claim_id: 966236c1aafd829ee691b98169036019c38ff122
  claim: Caris Life Sciences, Inc. entered into New Credit Agreement with Blue Owl Capital and Blackstone valued at Senior secured credit facilities: $400M initial term loan, $300M delayed draw, $500M incremental fac (effective 2026-04-01).
  evidence_excerpt: On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm
- claim_id: b6e34681e3b08597ea60b0af74694e236d6571a8
  claim: Caris Life Sciences, Inc. terminated Previous Credit Agreement with Wilmington Trust, National Association valued at Repaid all outstanding indebtedness and terminated guarantees, liens, and security interests under t (effective 2026-04-01).
  evidence_excerpt: On the Closing Date, the Company used proceeds under the Initial Term Facility to repay all outstanding indebtedness under that certain credit agreement, dated as of January 18, 2023, by and among the Company, certain of the Company’s subsidiaries, the lenders from time to time party thereto and Wilmington Trust, National Association, as administrative agent, as amended (the “ Previous Credit Agreement ”). The Company terminated all guarantees, liens and other security interests granted under and terminated the Previous Credit Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.